country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P1696

Copy Link Print Information

U 70714E

U 70714E is a Renin inhibitor with an IC₅₀ of 3.0 nM. U 70714E is used for the research of renin-related hypertension.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 114376-16-8
Formule: C₆₆H₇₆N₁₂O₁₀
Masse moléculaire:1197.38

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Synthèse personnalisée de peptides

U 70714E Chemical Structure

CAS No.: 114376-16-8

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
Chemical Information
Protocole (1)
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

U 70714E is a Renin inhibitor with an IC₅₀ of 3.0 nM. U 70714E is used for the research of renin-related hypertension^[1].

In Vitro

U 70714E potently inhibits plasma renin in vitro, with an IC₅₀ of 3.0 nM, which is 2700 times more potent than the reference compound RIP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Chemical Information

CAS No. 114376-16-8
Masse moléculaire 1197.38
Formule C₆₆H₇₆N₁₂O₁₀
Sequence

Ac-Trp(formyl)-Pro-Phe-His-Phe(deoxy)-Phe-Val-Tyr-NH2
Sequence Shortening

Ac-Trp(formyl)-PFH-Phe(deoxy)-FVY-NH2
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocole

All Signal Pathway Related

Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.

Pureté et documentation

Instruction de manipulation (2659 KB)

Références

[1]. Epps DE, et al. Structure-conformation relationships of synthetic peptide inhibitors of human renin studied by resonance energy transfer and molecular modeling. International journal of peptide and protein research. 1988 Jan;31(1):22-34.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis